Denali Therapeutics Inc.
BIIB122/DNL151
Parkinson’s disease
Resolved
47days ago
Phase 2 readout · May 21, 2026
What's at stake
Phase 2 trial results for BIIB122/DNL151 in Parkinson’s disease are due May 21, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“On May 21, 2026, Denali Therapeutics Inc. (the “Company”) and Biogen Inc. issued a press release announcing topline results from the Phase 2b LUMA study evaluating BIIB122 (DNL151) in individuals with early-stage Parkinson’s disease.”